Which of the following is a common IV HEC drug?

Carmustine is a common intravenous (IV) high emetic risk (HEC) chemotherapy drug. It belongs to the class of nitrosourea compounds and is known for its potential to cause significant nausea and vomiting, which classifies it as high emetic risk. Patients receiving carmustine often require preventive measures to manage these side effects, such as the use of antiemetic agents before treatment.

The other options listed, although they are chemotherapy agents, do not typically fall into the high emetic risk category in the same way that carmustine does. For example, bleomycin is generally considered to have a lower emetic potential, and while 5-FU (fluorouracil) can cause some level of nausea and vomiting, it is not classified with the same high emetic risk. Docetaxel, on the other hand, has a moderate emetic risk but is not as closely associated with HEC as carmustine is. Therefore, carmustine is recognized as a standard HEC agent in the context of IV chemotherapy options.